Advanced Energy Industries Stock And 2 More Growth Shares Worth Watching

With inflation trends diverging across regions, energy prices swinging around geopolitical headlines and central banks keeping investors on their toes, many readers are looking for companies that analysts expect to grow earnings while still keeping balance sheets in reasonable shape. That is exactly what the Healthy high growth potential screener tries to filter for, focusing on stocks where analysts see strong earnings growth over the next 3 years and financial positions that meet clear quality hurdles. In this article, you will see 3 stocks from the screener that could help you focus your research on this growth-oriented theme.

Aritzia (TSX:ATZ)

Overview: Aritzia is a Vancouver based fashion retailer that designs and sells a wide range of women’s clothing and accessories under its own brands, reaching customers through boutiques and a growing digital presence across Canada and the U.S.

Market Cap: CA$17.1b

Aritzia has caught attention because its U.S. expansion, digital push and new distribution center are associated with strong revenue growth, rising margins and high returns on equity, while analysts still see room between the current share price and their targets. At the same time, the company leans heavily on further U.S. boutique openings, higher marketing spend and external borrowings, so execution missteps or a weaker consumer would matter quickly. Recent record quarters, raised guidance and ongoing buybacks add to the appeal, but the elevated P/E and reliance on one major growth engine mean this is not a low risk story. Investors weighing growth against these trade offs may find Aritzia worth a closer look.

Aritzia’s rapid U.S. rollout, digital push and fresh distribution muscle may be masking a very different risk return profile than the headline P/E suggests, so it is worth scanning the 3 key rewards and 1 important warning sign

Kiniksa Pharmaceuticals International (KNSA)

Overview: Kiniksa Pharmaceuticals International is a biopharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet medical need, anchored by ARCALYST for recurrent pericarditis and a pipeline of monoclonal antibody programs such as KPL-387 and KPL-116.

Operations: Kiniksa generates about US$754.0m in revenue from developing and delivering therapeutic medicines.

Market Cap: US$5.0b

Kiniksa Pharmaceuticals International is drawing attention because ARCALYST is gaining wider adoption in recurrent pericarditis, driving strong revenue and earnings momentum while also funding further R&D without relying on external capital. Forecast double digit revenue and earnings growth, high payer coverage and improving margins sit alongside analyst targets that suggest the market may not fully reflect the long term potential if execution stays on track. At the same time, dependence on a single core product, a concentrated U.S. focus and rising competition keep risk firmly on the table, especially if clinical or pricing trends turn. For investors who want to understand how this balance of growth, concentration risk and valuation really stacks up, the analysis report for Kiniksa Pharmaceuticals International

Kiniksa’s ARCALYST story is accelerating; however, the real tension sits between that single product focus and what analysts expect next, so it is worth reading the analyst forecasts for Kiniksa Pharmaceuticals International to see what might be missing.

Advanced Energy Industries (AEIS)

Overview: Advanced Energy Industries develops precision power conversion, measurement, and control solutions that sit inside equipment used for semiconductor manufacturing, thin film processes, industrial production, medical devices, data centers, and telecommunications, helping customers manage power and temperature with high accuracy.

Operations: Advanced Energy Industries generates about US$1.9b in revenue, primarily from Power Electronics Conversion Products.

Market Cap: US$11.8b

Advanced Energy Industries stands out in the Healthy high growth potential screener because it sits at the heart of two powerful themes, AI data centers and advanced semiconductor equipment. It is already showing what strong execution can look like, with revenue of US$511m and net income of US$66.8m in the latest reported quarter alongside improved profit margins. Analysts expect earnings to grow quickly, helped by higher margin product platforms and a solid backlog across industrial and medical customers, even as the stock carries a high P/E and depends heavily on a small group of large hyperscale and chip equipment clients. For investors weighing that trade off between growth and customer concentration, the real question is how much of this earnings story might still be underappreciated.

Advanced Energy Industries sits at the crossroads of AI data centers and chip equipment, yet the full earnings path still feels underappreciated. It is worth reviewing the analyst forecasts for Advanced Energy Industries to see what the current expectations might be missing.

The three stocks covered here are only a sample of what analysts are seeing, with the full Healthy high growth potential screener surfacing 1,486 more companies that show similar earnings growth expectations and financial profiles, so it is worth checking the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction growth ideas that fit your own criteria.

Take Control of Your Investment Journey

If Kiniksa Pharmaceuticals International or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

Fresh stock ideas do not stay under the radar for long, and the best entry points can vanish once momentum gets flying, so review these focused lists regularly.

• Spot companies building early momentum across digital and traditional finance by running through the 20 cryptocurrency and blockchain stocks before the broader market reacts.
• Zero in on potential income-focused companies with resilient cash flows using the curated 6 dividend fortresses while yields and prices still appear attractive.
• Track companies involved in energy and infrastructure projects with the focused 89 nuclear energy infrastructure stocks before shifts in capital allocation change valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com